When Can Immunotherapy for Insect Sting Allergy Be Stopped?

Journal of Allergy and Clinical Immunology: In Practice

Volumn 3, Issue 3, 2015, Pages 324-328

  Müller, Ulrich R ^a   Ring, Johannes ^b,c  

^a Spital Netz Bern   (Switzerland)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c CHRISTINE KÜHNE CENTER FOR ALLERGY RESEARCH AND EDUCATION CK CARE   (Switzerland)

Author keywords

Duration of VIT; Efficacy of VIT; Honey bees; Hymenoptera venom allergy; Risk factors for recurrence after VIT; Venom immunotherapy; Vespids

Indexed keywords

BEE VENOM; ARTHROPOD VENOM;

AGE; ALLERGIC REACTION; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; CLINICAL EFFECTIVENESS; COUNSELING; DECISION MAKING; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DISEASE SEVERITY; HONEYBEE; HUMAN; IMMUNOTHERAPY; INSECT ALLERGY; LONG TERM CARE; LUNG DISEASE; MAST CELL; RECURRENCE RISK; RISK FACTOR; RISK REDUCTION; TREATMENT DURATION; VESPIDAE; ADVERSE EFFECTS; ANAPHYLAXIS; ANIMAL; CLASSIFICATION; DESENSITIZATION; HYMENOPTERA; HYPERSENSITIVITY; IMMUNOLOGY; INSECT BITES AND STINGS; PREDICTIVE VALUE; PROCEDURES; SKIN TEST; TIME FACTOR; TREATMENT OUTCOME;

ANAPHYLAXIS; ANIMALS; ARTHROPOD VENOMS; DESENSITIZATION, IMMUNOLOGIC; HUMANS; HYMENOPTERA; HYPERSENSITIVITY; INSECT BITES AND STINGS; PREDICTIVE VALUE OF TESTS; RISK FACTORS; SKIN TESTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84946038889     PISSN: 22132198     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaip.2014.11.018     Document Type: Article

References (46)

1. Sasvary T., Müller U. Deaths from insect stings in Switzerland 1978-87. Schweiz Med Wschr 1994, 124:1887-1894.
2. Hunt K.J., Valentine M.D., Sobotka A.K., Benton A.W., Amodia F.S., Lichtenstein L.M. A controlled trial of immunotherapy in insect venom hypersensitivity. N Engl J Med 1978, 299:157-161.
3. Müller U., Thurnheer U., Patrizzi R., Spiess J., Hoigné R. Immunotherapy in bee sting hypersensitivity. Allergy 1979, 34:369-378.
4. Brown S.G., Wiese M.D., Blackman K.E., Heddle R.J. Ant venom immunotherapy: a double-blind, placebo-controlled, crossover trial. Lancet 2003, 361:1001-1006.
5. Müller U., Helbling A., Berchtold E. Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety. J Allergy Clin Immunol 1992, 89:529-535.
6. Ruëff F., Przybilla B., Müller U., Mosbech H. The sting challenge test in Hymenoptera venom allergy. Position paper of the Subcommittee on Insect Venom Allergy of the European Academy of Allergology and Clinical Immunology. Allergy 1996, 51:216-225.
7. Bonifazi F., Jutel M., Biló B.M., Birnbaum J., Müller U., Bucher C., et al. Prevention and treatment of hymenoptera venom allergy: guidelines for clinical practice. Allergy 2005, 60:1459-1470.
8. Golden D.B., Moffitt J., Nicklas R.A., Freeman T., Graft D.F., Reisman R.E. Stinging insect hypersensitivity: a practice parameter update 2011. J Allergy Clin Immunol 2011, 127:852-854.
9. Boyle R.J., Elremeli M., Hockenhull J., Cherry M.G., Bulsara M.K., Oude Elberink J. Venom immunotherapy for preventing allergic reactions to insect stings. Cochrane Database Syst Rev 2012, 10:CD008838.
10. Pesek R.D., Lockey R.F. Treatment of Hymenoptera venom allergy: an update. Curr Opin Allergy Clin Immunol 2014, 14:340-346.
11. Golden D.B. Long-term outcome after venom immunotherapy. Curr Opin Allergy Clin Immunol 2010, 10:337-341.
12. Golden D.B., Johnson K., Addison B.I., Valentine M.D., Kagey-Sobotka A., Lichtenstein L.M. Clinical and immunologic observations in patients who stop venom immunotherapy. J Allergy Clin Immunol 1986, 77:435-442.
13. Lerch E., Müller U.R. Long-term protection after stopping venom immunotherapy: results of re-stings in 200 patients. J Allergy Clin Immunol 1998, 101:606-612.
14. Urbanek R., Forster J., Kuhn W., Ziupa J. Discontinuation of bee venom immunotherapy in children and adolescents. J Pediatr 1985, 107:367-371.
15. Von Moos S., Graf N., Johansen P., Müllner G., et al. Risk assessment of Hymenoptera re-sting: implications for decision-making in venom immunotherapy. Int Arch Allergy Immunol 2013, 160:86-92.
16. Müller U., Berchtold E., Helbling A. Honey bee venom allergy: results of a sting challenge 1 year after stopping successful venom immunotherapy in 86 patients. J Allergy Clin Immunol 1991, 87:702-709.
17. Haugaard L., Nørregaard O.F., Dahl R. In-hospital sting challenge in insect venom-allergic patients after stopping venom immunotherapy. J Allergy Clin Immunol 1991, 87:699-702.
18. Keating M.U., Kagey-Sobotka A., Hamilton R.G., Yunginger J.W. Clinical and immunologic follow-up of patients who stop venom immunotherapy. J Allergy Clin Immunol 1991, 88:339-348.
19. van Halteren H.K., van der Linden P.W., Burgers J.A., Bartelink A.K. Discontinuation of yellow jacket venom immunotherapy: follow-up of 75 patients by means of deliberate sting challenge. J Allergy Clin Immunol 1997, 100:767-770.
20. Golden D.B., Addison B.J., Gadde J., Kagey Sobotka A., Lichtenstein L.M. Prospective observations on stopping prolonged venom immunotherapy. J Allergy Clin Immunol 1989, 84:162-167.
21. Golden D.B., Kwiterovich K.A., Kagey-Sobotka A., Valentine M.D., Lichtenstein L.M. Discontinuing venom immunotherapy: outcome after five years. J Allergy Clin Immunol 1996, 97:579-587.
22. Golden D.B., Kagey-Sobotka A., Norman P.S., et al. Outcomes of allergy to insect stings in children, with and without venom immunotherapy. N Engl J Med 2004, 351:668-674.
23. Golden D.B., Kagey-Sobotka A., Lichtenstein L.M. Survey of patients after discontinuing venom immunotherapy. J Allergy Clin Immunol 2000, 105:385-390.
24. Müller U. Insect Sting Allergy: Clinical Picture, Diagnosis and Treatment 1990, Gustav/Fischer, Stuttgart, New York.
25. Reisman R.E. Duration of venom immunotherapy: relationship to the severity of symptoms of initial insect sting anaphylaxis. J Allergy Clin Immunol 1993, 92:831-836.
26. Golden D.B., Kwiterovich K.A., Kagey-Sobotka A., Lichtenstein L.M. Discontinuing venom immunotherapy: extended observations. J Allergy Clin Immunol 1998, 101:298-305.
27. Blaauw P.J., Smithuis L.O. The evaluation of the common diagnostic methods of hypersensitivity for bee and yellow jacket venom by means of an in-hospital insect sting. J Allergy Clin Immunol 1985, 75:556-562.
28. van der Linden P.W., Hack C.E., Struyvenberg A., van der Zwan J.K. Insect-sting challenge in 324 subjects with a previous anaphylactic reaction: current criteria for insect-venom hypersensitivity do not predict the occurrence and the severity of anaphylaxis. J Allergy Clin Immunol 1994, 94:151-159.
29. Ruëff F., Wenderoth A., Przybilla B. Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses. J Allergy Clin Immunol 2001, 108:1027-1032.
30. Ruëff F., Placzek M., Przybilla B. Mastocytosis and Hymenoptera venom allergy. Curr Opin Allergy Clin Immunol 2006, 6:284-288.
31. Mueller U.R. Cardiovascular disease and anaphylaxis. Curr Opin Allergy Clin Immunol 2007, 7:337-341.
32. Ruëff F., Vos B., Oude Elberink J., Bender A., Chatelain R., Dugas-Breit S., et al. Predictors of clinical effectiveness of Hymenoptera venom immunotherapy. Clin Exp Allergy 2014, 44:736-746.
33. Müller U.R., Horat W., Wüthrich B., Conroy M., Reisman R.E. Anaphylaxis after Hymenoptera stings in three patients with urticaria pigmentosa. J Allergy Clin Immunol 1983, 72:685-689.
34. Fricker M., Helbling A., Schwartz L., Müller U. Hymenoptera sting anaphylaxis and urticaria pigmentosa: clinical findings and results of venom immunotherapy in ten patients. J Allergy Clin Immunol 1997, 100:11-15.
35. Ludolph-Hauser D., Ruëff F., Fries C., Schöpf B., Przybilla B. Constitutively raised serum concentrations of mast-cell tryptase and severe anaphylactic reactions to Hymenoptera stings. Lancet 2001, 357:361-362.
36. Haeberli G., Brönnimann M., Hunziker T., Müller U. Elevated basal serum tryptase and Hymenoptera venom allergy: relation to severity of sting reactions and to safety and efficacy of venom immunotherapy. Clin Exp Allergy 2003, 33:1216-1220.
37. Ruëff F., Przybilla B., Biló M.B., Müller U., Scheipl F., Aberer W. Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase-a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity. J Allergy Clin Immunol 2009, 124:1047-1054.
38. Bonadonna P., Gonzalez-de-Olano D., Zanotti R., Riccio A., De Ferrari L., Lombardo C., et al. Venom immunotherapy in patients with clonal mast cell disorders: Efficacy, safety and practical considerations. J Allergy Clin Immunol Pract 2013, 1:474-478.
39. Niedoszytko M., Bonadonna P., Oude Elberink J., Golden D. Epidemiology, diagnosis and treatment of Hymenoptera venom allergy in mastocytosis patients. Immunol Allergy Clin North Am 2014, 34:365-381.
40. Sokol K.C., Ghazi A., Kelly B.C., Grant A. Omalzumab as a desensitizing agent and treatment in mastocytosis: a review of the literature and case report. J Allergy Clin Immunol Pract 2014, 2:266-270.
41. Wagner N., Fritze D., Przybilla B., Hagedorn M., Ruëff F. Fatal anaphylactic sting reaction in a patient with mastocytosis. Int Arch Allergy Immunol 2008, 146:162-163.
42. Oude Elberink J.N., de Monchy J.G., Kors J.W., van Doormal J.J., Dubois A.E. Fatal anaphylaxis after a yellow jacket sting, despite venom immunotherapy, in two patients with mastocytosis. J Allergy Clin Immunol 1997, 99:153-154.
43. Reimers A., Müller U. Fatal outcome of a Vespula sting in a patient with mastocytosis after specific immunotherapy with honey bee venom. J WAO Org 2005, 17:69-70.
44. Bonadonna P., Zanotti R., Müller U. Mastocytosis and insect venom allergy. Curr Opin Allergy Clin Immunol 2010, 10:347-353.
45. Hafner T., DuBuske L., Kosnik M. Long-term efficacy of venom immunotherapy. Ann Allergy Asthma Immunol 2008, 100:162-165.
46. Liebermann P., Golden D. When to discontinue venom immunotherapy: the role of retesting to venom. J Allergy Clin Immunol Pract 2013, 1:202-203.